NEUROSENSE THERAPEUTICS LTD
NRSN · NASDAQ
更新于 2026-10-14 09:31:18
- 今日最高
- $3.78
- 今日最低
- $3.36
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
K线图趋势，实际资料以交易页为准
关键数据
- 昨日开盘价
- $3.66
- 昨日收盘价
- $3.48
- 成交量
- 7424
- 市值
- $660.12万
- 本益比（P/E）
- --
- 每股收益（EPS）
- $-10.78
昨日价格区间
52周价格区间
公司概况
- 板块
- HEALTHCARE
- 行业
- Biotechnology
- 子行业
- BIOTECHNOLOGY
- 总部
- BUILDING B, HERZLIYA, ISRAEL, 4672562
- 国家
- IL
- 上市日期
- 2021-12-09
- 财年截止
- December
- 流通股数
- 3535万
- CIK
- 0001875091
Neurosense Therapeutics Ltd (NRSN) is a clinical-stage biotechnology firm dedicated to innovating treatments for neurodegenerative diseases, with a particular emphasis on Parkinson's disease. The company is advancing a diverse pipeline of therapeutic candidates through pivotal clinical trials, addressing critical unmet needs in neurology. With a seasoned management team and strategic partnerships, Neurosense is poised to develop groundbreaking therapies that not only enhance patient outcomes but also bolster its competitive position in the biopharmaceutical sector.
财务指标
营业收入
2025-12-31
--
2025-09-30
--
2025-06-30
--
2025-03-31
--
营业支出
2025-12-31
$319.65万
2025-09-30
$319.65万
2025-06-30
$234.6万
2025-03-31
$234.6万
净利润
2025-12-31
-$320.8万
2025-09-30
-$320.8万
2025-06-30
-$235.45万
2025-03-31
-$235.45万
净利润率
2025-12-31
--
2025-09-30
--
2025-06-30
--
2025-03-31
--
每股收益
2025-12-31
$0.00
2025-09-30
$-0.04
2025-06-30
$-0.19
2025-03-31
$-0.06
息税折旧摊销前利润
2025-12-31
-$319.25万
2025-09-30
-$319.25万
2025-06-30
-$234.2万
2025-03-31
-$234.2万
有效税率
2025-12-31
--
2025-09-30
--
2025-06-30
--
2025-03-31
--
| 项目 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| 营业收入 | -- | -- | -- | -- |
| 营业支出 | $319.65万 | $319.65万 | $234.6万 | $234.6万 |
| 净利润 | -$320.8万 | -$320.8万 | -$235.45万 | -$235.45万 |
| 净利润率 | -- | -- | -- | -- |
| 每股收益 | $0.00 | $-0.04 | $-0.19 | $-0.06 |
| 息税折旧摊销前利润 | -$319.25万 | -$319.25万 | -$234.2万 | -$234.2万 |
| 有效税率 | -- | -- | -- | -- |
常见问题
风险提示
股价可能大幅波动，短时间内可能出现显著涨跌。 数字资产与衍生品交易可能涉及杠杆、流动性等额外风险。 本页内容仅供参考，不构成任何投资建议。 产品可用性与访问可能因地区及适用法规而异。